Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Flamm

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Gastroenterology|February 12, 2009
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyThierry Poynard, Massimo Colombo, Jordi Bruix, et al.
Hepatology (Baltimore, Md.)|May 17, 2020
Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient CohortAhmed Gabr, Laura Kulik, Samdeep Mouli, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experienceRiad Salem, Ahmed Gabr, Ahsun Riaz, et al.
NEJM Evidence|January 28, 2025
Larsucosterol for the Treatment of Alcohol-Associated HepatitisMitchell Shiffman, Ben Da, Aparna Goel, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Gastroenterology|February 12, 2009
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyThierry Poynard, Massimo Colombo, Jordi Bruix, et al.
Hepatology (Baltimore, Md.)|May 17, 2020
Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient CohortAhmed Gabr, Laura Kulik, Samdeep Mouli, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experienceRiad Salem, Ahmed Gabr, Ahsun Riaz, et al.
NEJM Evidence|January 28, 2025
Larsucosterol for the Treatment of Alcohol-Associated HepatitisMitchell Shiffman, Ben Da, Aparna Goel, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Pageof 3